this vast entity also acts as a biochemical reservoir for intra-and extracellular communication between the different cardiac cells making the ECM extremely diverse in its function. 2 Peterfi et al. 3 describe for the first time a novel peroxidase homologue, peroxidasin-like protein (PXDNL), whose expression is exclusive to the heart. This work follows their previous research describing the role of peroxidasin (PXDN) in matrix deposition following a fibrotic stimulus in the kidney. 4 Intriguingly, both these proteins are derived from peroxidase-ancestors and have structural domains characteristic of 'classical' ECM proteins ( Figure 1 ). They include leucine-rich repeats similar to a subgroup of proteoglycans, such as decorin, mimecan, biglycan, and lumican, and which are important in collagen fibrillogenesis, 5 and a Von Willebrand factor domain as found in the ECM protein, von Willebrand A domain-related protein (WARP), which associates with perlecan and collagen type IV in the basement membrane. 6,7 PXDNL might also stimulate collagen cross-linking through its typical peroxidase domains, via dityrosine 8 or sulfilimine 9 bonds, showing the diverse nature of ECM regulators and the various ways in which collagens can be modified. This has led the authors to speculate that PXDNL, as for PXDN, may behave as a typical matrix protein, yet genetic evidence for its biological role modulating collagen cross-linking is lacking and will require additional protein-modifying studies.
The current paper clearly shows that PXDNL differs from the other peroxidase family members, in that it does not contain a functional catalytic domain involved in enzyme activity. While PXDN, like myeloperoxidase and others, contains a conserved amino acid sequence necessary for catalytic activity, PXDNL has two amino acids replaced, resulting in the lack of peroxidase activity. In addition, PXDNL is able to form a complex with PXDN acting as a functional antagonist and rendering PXDN catalytically inactive. Is there a need for a functional antagonist of peroxidase activity in the heart? The role of peroxidases in the cardiac health and disease is still poorly understood. Peroxidases in general catalyse the oxidation of substrates such as H 2 O 2 and are generally thought to be anti-oxidative enzymes. Yet their physiological function appears to be slightly more complex. Peroxidases, by either uncoupling endothelial nitric oxide synthase or oxidizing lipoproteins, promote vascular disease as illustrated by PXDN contributing to vascular dysfunction 10 and amplifying the role of reactive oxygen species (ROS) in oxidative injury following ischaemia reperfusion. 11 The diversity of peroxidase functions is further illustrated by neutrophil-derived myeloperoxidase which, following AngII stimulation, increases matrix metalloproteinases activity and enhances atrial fibrosis, resulting in atrial fibrillation. 12 In the heart, PXDN contributes to AngII-induced proliferation of vascular smooth muscle cells and down-regulation of the protein attenuated AngII-stimulated proliferation and is hence a mediator of AngII-stimulated peroxide formation. 13 So, would there be a benefit of PXDN inhibition by PXDNL during heart disease? The authors do not venture into a discussion about this, yet suggest that the selective expression of PXDNL in the heart might be due to the high ROS found within this metabolic intense organ. It is tempting to speculate that this is an evolutionary conserved mechanism that selectively buffers peroxidase activity during cardiac injury, and hence regulates cardiac inflammation and/or fibrosis, yet further research is required to investigate the role of PXDNL in the heart. Is there any clinical relevance to PXDNL? Peterfi et al. show that PXDNL (but not PXDN) increases upon heart failure, suggesting that under conditions of cardiac stress or injury, PXDNL may play a compensatory role. With exclusive expression in the heart and increased expression in response to AngII in iPS-cardiomyocytes, a potential adaptive function for PXDNL is suggested, yet the exact function of PXDNL in the heart remains to be discovered. The lack of PXDNL expression in rodents obstructs the development of gene-modified animals, making it difficult to fully dissect or manipulate the mechanisms by which PXDNL might contribute to heart failure. Most likely, the increase of PXDNL in heart failure aims to increase matrix stability by promoting collagen fibrillogenesis. This may prevent cardiac dilatation in ischaemic heart diseases, but might increase cardiac stiffness. Therefore, studying
The opinions expressed in this article are not necessarily those of the Editors of Cardiovascular Research or of the European Society of Cardiology. the differential expression of PXDN under diverse clinical pathologies such as ischaemia, hypertension, valvular heart disease, or in patients with atrial fibrillation might tell us more about its biological role and therapeutic prospects. Importantly, its expression is greater in the atria compared with the ventricles, suggesting a putative role in atrial arrhythmias concordant with previous findings for myeloperoxidase activity. 14 Finally, its cardiac-restricted expression makes it an excellent candidate as a biomarker, the most promising clinical application for PXDNL.
The discovery of this novel matrix protein with its multifunctional domains opens an exciting story in research, illustrating the variety of proteins found within, and the highly adaptive nature of the ECM.
